|
PHC Holdings Corporation is a holding company comprising three business domains: Diabetes Management, Healthcare Solutions, and Diagnostics & Life Science. The Diabetes Management domain develops, manufactures, and sells blood glucose monitoring systems and related consumables, primarily through subsidiaries PHC and Ascensia Diabetes Care Holdings AG, serving medical institutions and pharmacies globally. The Healthcare Solutions domain provides clinical testing services via LSI Medience, healthcare IT products such as electronic medical records and pharmacy systems through WeMacs, and contract research organization services including non-clinical trials and bioanalysis via Mediford. The Diagnostics & Life Science domain offers pathology equipment, biomedica devices like freezers and incubators, and point-of-care testing instruments, developed and sold by PHC and Epredia Holdings Ltd. subsidiaries. The group operates through a network of domestic and overseas subsidiaries, including PT PHC Indonesia for manufacturing and regional sales entities in North America, Europe, and Asia. Summarised from the annual report, fiscal year ended Mar 2026 |
Industry Medical Devices | Homepage phchd.com |
| Sector Healthcare | IR page phchd.com/global | |
|
Tags
blood glucose monitoring, clinical testing, healthcare it, contract research organization, pathology equipment, biomedical refrigeration, point-of-care testing, bioanalysis, electronic medical records, pharmacy systems, PHC, Ascensia Diabetes Care Holdings AG, Epredia Holdings Ltd., LSI Medience, WeMacs, Mediford, PT PHC Indonesia, PHC Corporation of North America, PHC Europe B.V., PHC Shanghai Co. Ltd., SciMed (ASIA) Pte Ltd, PT PHC Sales Indonesia, Epredia Laboratory Products Manufacturing (Shanghai) Co. Ltd.
|
Press page phchd.com/jp/news |
Metrics
| Valuation | |
|---|---|
| Market cap | ¥ 183.861B |
| Market cap (USD) | $ 1.149B |
| P/E | 12.75 |
| PEG | — |
| P/BV | 1.09 |
| P/S | 0.50 |
| P/OCF | 3.57 |
| P/FCF | 4.35 |
| Dividend yield | 2.9% |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | 0.33% |
| ROI | 0.12% |
| ROIC | 2.9% |
| Profit margin | 0.14% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | No |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 38 |
| Quality score | -22.2% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 364.403B | 361.593B | 353.9B | 356.434B | 340.452B | 306.071B | 272.637B | 186.546B | 6.683B |
| Net profit | 492M | 10.485B | -12.893B | -3.222B | -8.46B | 16.906B | 5.276B | 15.453B | 757M |
| Free cash flow | 33.365B | 30.331B | 26.674B | 9.86B | 39.317B | — | — | — | — |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||
| Trade receivables (JPY) | 63.5B | 63.7B | 69.3B | 73.8B | 70.5B | 70.3B |
| ↳ YoY growth | +0.4% | +8.7% | +6.5% | -4.4% | -0.4% | |
| ↳ 5y CAGR | +2.1% | |||||
| Borrowings, current (JPY) | 321B | 27.3B | 30.2B | 36.9B | 34.3B | 78.3B |
| Borrowings, non-current (JPY) | 67M | 281B | 262B | 248B | 221B | 156B |
| Cash and deposits (JPY) | 60.8B | 95.2B | 60.9B | 47B | 39.6B | 39.8B |
| Intangible assets (JPY) | 109B | 99.1B | 91.1B | 91.4B | 80.6B | 74.4B |
| Right-of-use assets (JPY) | 14.6B | 13B | 12.6B | 12.8B | 12.3B | 15.1B |
| Net debt (borrowings + leases - cash) (JPY) | 261B | 213B | 232B | 238B | 216B | 195B |
| Cash flow detail | ||||||
| Operating cash flow (JPY) | 47.9B | 51.1B | 21.4B | 41.3B | 41.9B | 42.5B |
| Purchases of property, plant and equipment (JPY) | -12.2B | -11.7B | -11.5B | -14.6B | -11.6B | -9.09B |
| Change in receivables (cash effect) (JPY) | -6.63B | 107M | -969M | 3.06B | 3.06B | 3.99B |
| Change in inventories (cash effect) (JPY) | -2.42B | -3.82B | -4.49B | 4.37B | -193M | 2.23B |
| Change in payables (cash effect) (JPY) | 4.77B | -354M | -7.42B | -1.48B | -2.6B | 2.92B |
| Dividends paid (cash effect) (JPY) | — | — | -9.2B | -9.04B | -4.92B | -5.31B |
| Share buybacks (cash effect) (JPY) | -588M | -359M | — | — | — | — |
| Interest paid (cash effect) (JPY) | -4.42B | -3.01B | -5.18B | -5.94B | -6.57B | -5.33B |
| Income taxes paid (cash effect) (JPY) | -3.69B | -7.09B | -15.4B | -6.85B | -3.98B | -7.02B |
| Operating cash flow before change in receivables (JPY) | 54.5B | 50.9B | 22.3B | 38.2B | 38.9B | 38.5B |
| Free cash flow (OCF - PPE - intangibles) (JPY) | 35.7B | 39.3B | 9.86B | 26.7B | 30.3B | 33.4B |
| Income detail | ||||||
| Research and development expense (JPY) | — | 10.3B | 9.93B | 12B | 10.7B | 10.9B |
| Total comprehensive income (JPY) | 26.2B | 3.74B | 11.2B | 11.9B | 6.28B | 24.1B |
| Comprehensive income to owners (JPY) | 26.2B | 3.51B | 10.9B | 11.9B | 6.4B | 24.5B |
| Segments | ||||||
| Diabetes Management · Segment revenue (JPY) | 108B | 109B | 112B | 109B | 98.7B | 102B |
| ↳ YoY growth | +1.1% | +2.2% | -2.5% | -9.5% | +2.9% | |
| Diabetes Management · Segment operating income (JPY) | 23.9B | 23.3B | 26.7B | 15.3B | 13.9B | 20.1B |
| Diagnostics And Life Sciences · Segment revenue (JPY) | 79.9B | 92.2B | 109B | 109B | 131B | 128B |
| ↳ YoY growth | +15.5% | +17.9% | +0.3% | +20.1% | -2.0% | |
| Diagnostics And Life Sciences · Segment operating income (JPY) | 508M | -14.1B | -1.07B | 6.02B | 7.25B | 3.89B |
| Healthcare Solutions · Segment revenue (JPY) | 116B | 136B | 134B | 133B | 128B | 128B |
| ↳ YoY growth | +17.4% | -2.0% | -0.1% | -3.8% | +0.1% | |
| Healthcare Solutions · Segment operating income (JPY) | 4.51B | 17B | 9.83B | -9.15B | 9.27B | 6.23B |
| Reported | Jun 29, 2022 | Jun 29, 2022 | Jun 23, 2023 | Jun 26, 2024 | Jun 25, 2025 | Jun 23, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpTimely disclosures published on TDnet, newest first, titles as filed in Japanese. The link opens the disclosure on TDnet. Filings with EDINET (periodic reports, extraordinary reports, offerings, holding and buy-back reports), newest first, titles as filed in Japanese. The link opens the filing on EDINET. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding PHC Holdings Corporation
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| DISV | 0.05% | 289,400 | $ 2.324M | Nov 12, 2026 |
| DFIS | 0.01% | 96,200 | $ 772.488K | Nov 12, 2026 |
| AVDS | 0.01% | 3,600 | $ 28.312K | Nov 16, 2026 |
| DXIV | 0.01% | 2,900 | $ 23.287K | Nov 12, 2026 |
| DFIC | 0.00% | 75,100 | $ 603.054K | Nov 12, 2026 |
| DFSI | 0.00% | 4,300 | $ 34.529K | Nov 12, 2026 |
| DFAI | 0.00% | 47,404 | $ 380.655K | Nov 12, 2026 |
| DFAX | 0.00% | 29,100 | $ 233.674K | Nov 12, 2026 |





























会社概要
環境活動
健康経営












